Barry R. Walker
Gründer bei American Society of Hypertension
Profil
Barry R.
Walker is the founder of American Society of Hypertension.
He worked as a Senior Vice President of Research & Development at Wyeth-Ayerst Research and as an Adjunct Associate Professor of Medicine at the University of Pennsylvania.
He also served as an Independent Non-Executive Director at Botanix Pharmaceuticals Ltd.
and as SVP-Regulatory & Clinical Development at Ceptaris Therapeutics, Inc. He holds a doctorate from The Trustees of Columbia University in The City of New York and an undergraduate degree from Yale University.
Aktive Positionen von Barry R. Walker
Unternehmen | Position | Beginn |
---|---|---|
American Society of Hypertension | Gründer | 16.03.2011 |
Ehemalige bekannte Positionen von Barry R. Walker
Unternehmen | Position | Ende |
---|---|---|
University of Pennsylvania | Corporate Officer/Principal | - |
BOTANIX PHARMACEUTICALS LIMITED | Direktor/Vorstandsmitglied | 19.08.2011 |
Wyeth-Ayerst Research | Technik-/Wissenschafts-/F&E-Leiter | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | General Counsel | 22.03.2011 |
Ausbildung von Barry R. Walker
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Yale University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BOTANIX PHARMACEUTICALS LIMITED | Health Technology |
Private Unternehmen | 3 |
---|---|
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Wyeth-Ayerst Research | |
American Society of Hypertension |